Exothera

NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

16 August 2023 — Maryland, US and Jumet, Belgium — The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera, a full-service Contract Development and Manufacturing Organisation (CDMO) specialised in gene therapy, vaccines, oncolytic viruses and nucleic acid-based therapeutics, to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2. As part…

Exothera announces a strategic partnership with Quantoom Biosciences and launches a new business unit for the development and production of RNA

26 April 2023 — Brussels, Belgium — Exothera has partnered with Quantoom Biosciences (“Quantoom”) to gain access to Quantoomís Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous…
Zoning de Jumet, Allée Centrale 52, 6040 Jumet – BELGIUM

+32 (0) 71 49 67 22